Disorders of the metabolism, including obesity and type 2 diabetes, represent significant global health challenges due to their rising prevalence and associated complications. Despite existing therapeutic strategies, including lifestyle interventions, pharmacological treatments, and surgical options, limitations such as poor adherence, side effects, and accessibility issues call attention to the need for novel solutions. Tetrahydrocannabivarin (THCV), a non-psychoactive cannabinoid derived from Cannabis sativa, has emerged as a promising agent to manage metabolic disorders. Unlike tetrahydrocannabinol (THC), THCV exhibits an antagonistic function on the CB1 receptor and a partial agonist function on the CB2 receptor, thus enabling appetite suppression, enhanced glucose regulation, and increased energy expenditure. Preclinical studies demonstrated that THCV improves insulin sensitivity, promotes glucose uptake, and restores insulin signaling in metabolic tissues. Additionally, THCV reduces lipid accumulation and improves the mitochondrial activity in adipocytes and hepatocytes, shown through both cell-based and animal research. Animal models further revealed THCV's potential to suppress appetite, prevent hepatosteatosis, and improve metabolic homeostasis. Preliminary human trials support these findings, thereby showing that THCV may modulate appetite and glycemic control, though larger-scale studies are necessary to confirm its clinical efficacy and safety. THCV's unique pharmacological profile positions it as a possible therapeutic candidate to address the multifaceted challenges of obesity and diabetes. Continued research should concentrate on optimizing formulations, undertaking well-designed clinical studies, and addressing regulatory hurdles to unlock its full potential.
Citation: Scott Mendoza. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management[J]. AIMS Neuroscience, 2025, 12(1): 32-43. doi: 10.3934/Neuroscience.2025003
[1] | Brojeswar Pal, Anindya Mandal, Shib Sankar Sana . A closed-loop green supply chain with retailers' competition and product recycling in the green environment under the cap-and-trade policy. Green Finance, 2024, 6(1): 117-161. doi: 10.3934/GF.2024006 |
[2] | Massimiliano Calvia . Fossil energy use and carbon emissions: An easy-to-implement technical policy experiment. Green Finance, 2024, 6(3): 407-429. doi: 10.3934/GF.2024016 |
[3] | Sameh Halaoua, Sonia Boukattaya . Does gender diversity in the audit committee influence corporate dividend policy? Evidence from French listed firms. Green Finance, 2023, 5(3): 373-391. doi: 10.3934/GF.2023015 |
[4] | Memoona Kanwal, Hashim Khan . Does carbon asset add value to clean energy market? Evidence from EU. Green Finance, 2021, 3(4): 495-507. doi: 10.3934/GF.2021023 |
[5] | Rui M. Pereira, Alfredo M. Pereira . Financing a renewable energy feed-in tariff with a tax on carbon dioxide emissions: A dynamic multi-sector general equilibrium analysis for Portugal. Green Finance, 2019, 1(3): 279-296. doi: 10.3934/GF.2019.3.279 |
[6] | Colin Nolden . Collecting silences: creating value by assetizing carbon emission mitigations and energy demand reductions. Green Finance, 2022, 4(2): 137-158. doi: 10.3934/GF.2022007 |
[7] | Tadhg O'Mahony . State of the art in carbon taxes: a review of the global conclusions. Green Finance, 2020, 2(4): 409-423. doi: 10.3934/GF.2020022 |
[8] | Luis Antonio López, Raquel López . What can green investors learn from funds' value chain carbon footprint? Evidence from Spain. Green Finance, 2025, 7(2): 332-362. doi: 10.3934/GF.2025012 |
[9] | Jieqiong Yang, Panzhu Luo . Review on international comparison of carbon financial market. Green Finance, 2020, 2(1): 55-74. doi: 10.3934/GF.2020004 |
[10] | Jaspreet K. Sra, Annie L. Booth, Raymond A. K. Cox . Voluntary carbon information disclosures, corporate-level environmental sustainability efforts, and market value. Green Finance, 2022, 4(2): 179-206. doi: 10.3934/GF.2022009 |
Disorders of the metabolism, including obesity and type 2 diabetes, represent significant global health challenges due to their rising prevalence and associated complications. Despite existing therapeutic strategies, including lifestyle interventions, pharmacological treatments, and surgical options, limitations such as poor adherence, side effects, and accessibility issues call attention to the need for novel solutions. Tetrahydrocannabivarin (THCV), a non-psychoactive cannabinoid derived from Cannabis sativa, has emerged as a promising agent to manage metabolic disorders. Unlike tetrahydrocannabinol (THC), THCV exhibits an antagonistic function on the CB1 receptor and a partial agonist function on the CB2 receptor, thus enabling appetite suppression, enhanced glucose regulation, and increased energy expenditure. Preclinical studies demonstrated that THCV improves insulin sensitivity, promotes glucose uptake, and restores insulin signaling in metabolic tissues. Additionally, THCV reduces lipid accumulation and improves the mitochondrial activity in adipocytes and hepatocytes, shown through both cell-based and animal research. Animal models further revealed THCV's potential to suppress appetite, prevent hepatosteatosis, and improve metabolic homeostasis. Preliminary human trials support these findings, thereby showing that THCV may modulate appetite and glycemic control, though larger-scale studies are necessary to confirm its clinical efficacy and safety. THCV's unique pharmacological profile positions it as a possible therapeutic candidate to address the multifaceted challenges of obesity and diabetes. Continued research should concentrate on optimizing formulations, undertaking well-designed clinical studies, and addressing regulatory hurdles to unlock its full potential.
The micropolar fluid model is a qualitative generalization of the well-known Navier-Stokes model in the sense that it takes into account the microstructure of fluid [7]. The model was first derived in 1966 by Eringen [4] to describe the motion of a class of non-Newtonian fluid with micro-rotational effects and inertia involved. It can be expressed by the following equations:
{∂u∂t−(ν+νr)Δu−2νrrotω+(u⋅∇)u+∇p=f,∂ω∂t−(ca+cd)Δω+4νrω+(u⋅∇)ω−(c0+cd−ca)∇divω−2νrrotu=˜f,∇⋅u=0, | (1) |
where
Micropolar fluid models play an important role in the fields of applied and computational mathematics. There is a rich literature on the mathematical theory of micropolar fluid model. Particularly, the existence, uniqueness and regularity of solutions for the micropolar fluid flows have been investigated in [6]. Extensive studies on long time behavior of solutions for the micropolar fluid flows have also been done. For example, in the case of 2D bounded domains: Łukaszewicz [7] established the existence of
As we know, in the real world, delay terms appear naturally, for instance as effects in wind tunnel experiments (see [10]). Also the delay situations may occur when we want to control the system via applying a force which considers not only the present state but also the history state of the system. The delay of partial differential equations (PDE) includes finite delays (constant, variable, distributed, etc) and infinite delays. Different types of delays need to be treated by different approaches.
In this paper, we consider the situation that the velocity component
There exists λ1>0 such that λ1‖φ‖2L2(Ω)≤‖∇φ‖2L2(Ω), ∀φ∈H10(Ω). | (2) |
Then we discuss the following 2D non-autonomous incompressible micropolar fluid flows with finite delay:
{∂u∂t−(ν+νr)Δu−2νr∇×ω+(u⋅∇)u+∇p=f(t,x)+g(t,ut),in(τ,+∞)×Ω,∂ω∂t−ˉαΔω+4νrω−2νr∇×u+(u⋅∇)ω=˜f(t,x)+˜g(t,ωt),in(τ,+∞)×Ω,∇⋅u=0,in(τ,+∞)×Ω, | (3) |
where
ut(s):=u(t+s), ωt(s):=ω(t+s), ∀t≥τ, s∈(−h,0). |
where
∇×u:=∂u2∂x1−∂u1∂x2,∇×ω:=(∂ω∂x2,−∂ω∂x1). |
To complete the formulation of the initial boundary value problem to system (3), we give the following initial boundary conditions:
(u(τ),ω(τ))=(uin,ωin), (uτ(s),ωτ(s))=(ϕin1(s),ϕin2(s)), s∈(−h,0), | (4) |
u=0, ω=0,on(τ,+∞)×Γ. | (5) |
For problem (3)-(5), Sun and Liu established the existence of pullback attractor in [16], recently.
The first purpose of this work is to investigate the boundedness of the pullback attractor obtained in [16]. We remark that García-Luengo, Marín-Rubio and Real [5] proved the
The second purpose of this work is to investigate the upper semicontinuity of the pullback attractor with respect to the domain
Throughout this paper, we denote the usual Lebesgue space and Sobolev space by
V:=V(Ω):={φ∈C∞0(Ω)×C∞0(Ω)|φ=(φ1,φ2),∇⋅φ=0},ˆV:=ˆV(Ω):=V×C∞0(Ω),H:=H(Ω):=closureofVinL2(Ω)×L2(Ω),withnorm‖⋅‖H anddualspaceH∗,V:=V(Ω):=closureofVinH1(Ω)×H1(Ω),withnorm‖⋅‖V anddualspaceV∗,ˆH:=ˆH(Ω):=closureofˆVinL2(Ω)×L2(Ω)×L2(Ω),withnorm‖⋅‖ˆH anddualspaceˆH∗,ˆV:=ˆV(Ω):=closureofˆVinH1(Ω)×H1(Ω)×H1(Ω),withnorm‖⋅‖ˆV anddualspaceˆV∗. |
Lp(I;X):=space of strongly measurable functions on the closed interval I, with values in the Banach space X, endowed with norm‖φ‖Lp(I;X):=(∫I‖φ‖pXdt)1/p, for 1≤p<∞,C(I;X):=space of continuous functions on the interval I, with values in the Banach space X, endowed with the usual norm, L2loc(I;X):=space of locally square integrable functions on the interval I, with values in the Banach space X, endowed with the usual norm,distM(X,Y)− the Hausdorff semidistance between X⊆MandY⊆MdefinedbydistM(X,Y)=supx∈Xinfy∈YdistM(x,y). |
Following the above notations, we additionally denote
L2ˆH:=L2(−h,0;ˆH),L2ˆV:=L2(−h,0;ˆV), E2ˆH:=ˆH×L2ˆH, E2ˆV:=ˆV×L2ˆV, E2ˆH×L2ˆV:=ˆH×L2ˆV. |
The norm
‖(w,v)‖E2ˆH:=(‖w‖2ˆv+‖v‖2L2ˆH)1/2,‖(w,v)‖E2ˆV:=(‖w‖2+‖v‖2L2ˆV)1/2,‖(w,v)‖E2ˆH×L2ˆV:=(‖w‖2+‖v‖2L2ˆV)1/2. |
The rest of this paper is organized as follows. In section 2, we make some preliminaries. In section 3, we investigate the boundedness of the pullback attractor. In section 4, we prove the upper semicontinuity of the pullback attractor with respect to the domains.
In this section, for the sake of discussion, we first introduce some useful operators and put problem (3)-(5) into an abstract form. Then we recall some important known results about the non-autonomous micropolar fluid flows.
To begin with, we define the operators
{⟨Aw,φ⟩:=(ν+νr)(∇u,∇Φ)+ˉα(∇ω,∇φ3), ∀w=(u,ω),φ=(Φ,φ3)∈ˆV,⟨B(u,w),φ⟩:=((u⋅∇)w,φ), ∀u∈V,w=(u,ω)∈ˆV,∀φ∈ˆV,N(w):=(−2νr∇×ω,−2νr∇×u+4νrω), ∀w=(u,ω)∈ˆV. | (6) |
What follows are some useful estimates and properties for the operators
Lemma 2.1.
⟨B(u,ψ),φ⟩=−⟨B(u,φ),ψ⟩, ∀u∈V, ∀ψ∈ˆV, ∀φ∈ˆV. | (7) |
Lemma 2.2.
c1⟨Aw,w⟩≤‖w‖2ˆV≤c2⟨Aw,w⟩, ∀w∈ˆV. | (8) |
|⟨B(u,ψ),φ⟩|≤{α0‖u‖12‖∇u‖12‖φ‖12‖∇φ‖12‖∇ψ‖,α0‖u‖12‖∇u‖12‖ψ‖12‖∇ψ‖12‖∇φ‖. | (9) |
Moreover, if
|⟨B(u,ψ),Aφ⟩|≤α0‖u‖12‖∇u‖12‖∇ψ‖12‖Aψ‖12‖Aφ‖. | (10) |
‖N(ψ)‖≤c(νr)‖ψ‖ˆV, ∀ψ∈ˆV. | (11) |
In addition,
δ1‖ψ‖2ˆV≤⟨Aψ,ψ⟩+⟨N(ψ),ψ⟩, ∀ψ∈ˆV, | (12) |
where
According to the definitions of operators
{∂w∂t+Aw+B(u,w)+N(w)=F(t,x)+G(t,wt),in (τ,+∞)×Ω,∇⋅u=0,in (τ,+∞)×Ω,w=(u,ω)=0, on (τ,+∞)×Γ,w(τ)=(uin,ωin)=:win, wτ(s)=(uτ(s),ωτ(s))=(ϕin1(s),ϕin2(s)) =:ϕin(s), s∈(−h,0), | (13) |
where
w:=(u(t,x),ω(t,x)),F(t,x):=(f(t,x),˜f(t,x)),G(t,wt):=(g(t,ut),˜g(t,ωt)). |
Before recalling the known results for problem (13), we need to make the following assumptions with respect to
Assumption 2.1. Assume that
(ⅰ) For any
(ⅱ)
(ⅲ) There exists a constant
‖G(t,ξ)−G(t,η)‖≤LG‖ξ−η‖L2(−h,0;ˆH). |
(ⅳ) There exists
∫tτ‖G(θ,wθ)−G(θ,vθ)‖2dθ≤C2G∫tτ−h‖w(θ)−v(θ)‖2dθ. |
Assumption 2.2. Assume that
∫t−∞eγθ‖F(θ,x)‖2ˆV∗dθ<+∞. | (14) |
In order to facilitate the discussion, we denote by
Definition 2.3. (Definition of universe
Rγ:={ρ(t):R↦R+ | limt→−∞eγtρ2(t)=0}. |
We denote by
D(t)⊆ˉBE2ˆH(0,ρˆD(t)), for some ρˆD(t)∈Rγ, |
where
Based on the above assumptions, we can recall the global well-posedness of solutions and the existence of pullback attractor of problem (13).
Proposition 2.1. (Existence and uniqueness of solution, see [13,16])
Let Assumption 2.1 and Assumption 2.2 hold. Then for any
w∈C([τ,T];ˆH)∩L2(τ,T;ˆV) and w′∈L2(τ,T;ˆV∗), ∀T>τ. |
Remark 2.1. According to Proposition 2.1, the biparametric mapping defined by
U(t,τ):(win,ϕin(s))↦(w(t;τ,win,ϕin(s)),wt(s;τ,win,ϕin(s))), ∀t≥τ, | (15) |
generates a continuous process in
(i)U(τ,τ)(win,ϕin(s))=(win,ϕin(s)), |
(ii)U(t,θ)U(θ,τ)(win,ϕin(s))=U(t,τ)(win,ϕin(s)). |
Proposition 2.2. (Existence of pullback attractor, see [16]) Under the Assumption 2.1 and Assumption 2.2, there exists a pullback attractor
limτ→−∞distE2ˆH(U(t,τ)B(τ),AˆH(t))=0, ∀t∈R; |
limτ→−∞distE2ˆH(U(t,τ)B(τ),O(t))=0, for anyˆB={B(θ)|θ∈R}∈Dγ, |
then
Finally, we introduce a useful lemma, which plays an important role in the proof of higher regularity of the pullback attractor.
Lemma 2.4. (see [12]) Let X, Y be Banach spaces such that X is reflexive, and the inclusion
‖w(θ)‖X≤lim infn→+∞‖wn(θ)‖L∞(τ,t;X), ∀θ∈[τ,t]. |
This section is devoted to investigating the boundedness of the pullback attractor for the universe
wn(t)=wn(t;τ,win,ϕin(s))=n∑j=1ξnj(t)ej, wnt(⋅)=wn(t+⋅), | (16) |
where the sequence
ej∈D(A) and Aej=λjej, | (17) |
where the eigenvalues
0<λ1≤λ2≤⋯≤λj≤⋯, λj→+∞ as j→∞. |
It is not difficult to check that
{ddt(wn(t),ej)+⟨Awn(t)+B(un,wn)+N(wn(t)),ej⟩ =⟨F(t),ej⟩+(G(t,wnt),ej),(wn(τ),ej)=(win,ej), (wnτ(s),ej)=(ϕin(s),ej),s∈(−h,0), j=1,2,⋯,n. | (18) |
Next we verify the following estimates of the Galerkin approximate solutions defined by (16).
Lemma 3.1. Let Assumption (2.1) and Assumption (2.2) hold. Then for any
(ⅰ) the set
(ⅱ) the set
(ⅲ) the set
(ⅳ) the set
Proof. Multiplying (18) by
12ddt‖wn(t)‖2+δ1‖wn(t)‖2ˆV≤12ddt‖wn(t)‖2+⟨Awn(t),wn(t)⟩+⟨N(wn(t)),wn(t)⟩+⟨B(un,wn),wn(t)⟩=⟨F(t),wn(t)⟩+(G(t,wnt),wn(t)). |
Then integrating the above inequality over
‖wn(t)‖2+2δ1∫tτ‖wn(θ)‖2ˆVdθ≤‖win‖2+(δ1−CG)∫tτ‖wn(θ)‖2ˆVdθ+1δ1−CG∫tτ‖F(θ)‖2ˆV∗dθ+CG∫tτ‖wn(θ)‖2dθ+1CG∫tτ‖G(θ,wnθ)‖2dθ≤‖win‖2+(δ1−CG)∫tτ‖wn(θ)‖2ˆVdθ+1δ1−CG∫tτ‖F(θ)‖2ˆV∗dθ+CG∫tτ‖wn(θ)‖2dθ+CG(∫tτ‖wn(θ)‖2dθ+∫0−h‖ϕin(s)‖2ds), |
which implies
‖wn(t)‖2+(δ1−CG)∫tτ‖wn(θ)‖2ˆVdθ≤max{1,CG}‖(win,ϕin)‖2E2ˆH+1δ1−CG∫tτ‖F(θ)‖2ˆV∗dθ. | (19) |
Thanks to (17), multiplying (18) by
12ddt⟨Awn(t),wn(t)⟩+‖Awn(t)‖2+⟨B(un,wn),Awn(t)⟩+⟨N(wn(t)),Awn(t)⟩=(F(t),Awn(t))+(G(t,wnt),Awn(t)). |
Observe that
|⟨B(un,wn),Awn(t)⟩|+|⟨N(wn(t)),Awn(t)⟩|≤α0‖un‖12‖∇un‖12‖∇wn‖12‖Awn‖12‖Awn‖+14‖Awn(t)‖2+c2(νr)‖wn(t)‖2ˆV≤12‖Awn(t)‖2+43α40‖wn(t)‖2‖wn(t)‖4ˆV+c2(νr)‖wn(t)‖2ˆV |
and
(F(t),Awn(t))+(G(t,wnt),Awn(t))≤14‖Awn(t)‖2+2‖F(t)‖2+2‖G(t,wnt)‖2. |
Therefore
ddt⟨Awn(t),wn(t)⟩+12‖Awn(t)‖2≤4‖F(t)‖2+4‖G(t,wnt)‖2+128α40‖wn(t)‖2‖wn(t)‖4ˆV+2c2(νr)‖wn(t)‖2ˆV≤4‖F(t)‖2+4‖G(t,wnt)‖2+(128c2α40‖wn(t)‖2‖wn(t)‖2ˆV+2c2c2(νr))⟨Awn(t),wn(t)⟩. | (20) |
Set
Hn(θ):=⟨Awn(θ),wn(θ)⟩,In(θ):=4‖F(θ)‖2+4‖G(θ,wnθ)‖2,Jn(θ):=128c2α40‖wn(θ)‖2‖wn(θ)‖2ˆV+2c2c2(νr), |
then we get
ddθHn(θ)≤Jn(θ)Hn(θ)+In(θ). | (21) |
By Gronwall inequality, (21) yields
Hn(r)≤(Hn(˜r)+∫rr−ϵIn(θ)dθ)⋅exp{∫rr−ϵJn(θ)dθ}, ∀τ≤r−ϵ≤˜r≤r≤t. |
Integrating the above inequality for
ϵHn(r)≤(∫rr−ϵHn(˜r)d˜r+ϵ∫rr−ϵIn(θ)dθ)⋅exp{∫rr−ϵJn(θ)dθ}. |
Since
∫rr−ϵHn(˜r)d˜r+ϵ∫rr−ϵIn(θ)dθ=∫rr−ϵ⟨Awn(˜r),wn(˜r)⟩d˜r+4ϵ∫rr−ϵ(‖F(θ)‖2+‖G(θ,wnθ)‖2)dθ≤1c1∫tτ‖wn(θ)‖2ˆVdθ+4ϵ∫tτ‖F(θ)‖2dθ+4ϵC2G(∫tτ‖wn(θ)‖2dθ+∫0−h‖ϕin(s)‖2ds), |
∫rr−ϵJn(θ)dθ=128c2α40∫rr−ϵ‖wn(θ)‖2‖wn(θ)‖2ˆVdθ+2ϵc2c2(νr)≤128c2α40maxθ∈[τ,t]‖wn(θ)‖2∫tτ‖wn(θ)‖2ˆVdθ+2ϵc2c2(νr), |
we can conclude that
‖wn(r)‖2ˆV≤c2Hn(r)≤[c2c1ϵ∫tτ‖wn(θ)‖2ˆVdθ+4c2∫tτ‖F(θ)‖2dθ +4c2C2G(∫tτ‖wn(θ)‖2dθ+∫0−h‖ϕin(s)‖2ds)]⋅exp{128c2α40maxθ∈[τ,t]‖wn(θ)‖2∫tτ‖wn(θ)‖2ˆVdθ+2ϵc2c2(νr)}, |
which together with (19) and Assumption 2.2 implies the assertion (i).
Now, integrating (20) over
∫tτ+ϵ‖Awn(θ)‖2dθ≤2c1‖wn(τ+ϵ)‖2ˆV+8∫tτ‖F(θ)‖2dθ+8C2G(∫tτ‖wn(θ)‖2dθ+∫0−h‖ϕin(s)‖2ds)+(256α40maxθ∈[τ+ϵ,t](‖wn(θ)‖‖wn(θ)‖ˆV)2+4c2(νr))∫tτ+ϵ‖wn(θ)‖2ˆVdθ, |
which together with (19), Assumption 2.2 and the assertion (ⅰ) gives the assertion (ⅲ).
In addition,
∫0−h‖wnr(θ)‖2ˆVdθ=∫rr−h‖wn(θ)‖2ˆVdθ≤h⋅maxθ∈[τ+ϵ,t]‖wn(θ)‖2ˆV,τ+h+ϵ≤r≤t, | (22) |
which together with the assertion (ⅰ) yields the assertion (ⅱ).
Finally, multiplying (18) by
‖w′n(t)‖2+12ddt⟨Awn(t),wn(t)⟩+⟨B(un,wn),w′n(t)⟩+⟨N(wn(t)),w′n(t)⟩=(F(t),w′n(t))+(G(t,wnt),w′n(t)). | (23) |
From Assumption 2.1, it follows that
(F(t),w′n(t))+(G(t,wnt),w′n(t))≤(‖F(t)‖+‖G(t,wnt)‖)‖w′n(t)‖≤2‖F(t)‖2+2‖G(t,wnt)‖2+14‖w′n(t)‖2. | (24) |
By Lemma 2.2,
|⟨B(un,wn),w′n(t)⟩|≤α0‖un‖12‖∇un‖12‖∇wn‖12‖Awn‖12‖w′n(t)‖≤α0‖wn‖12‖wn‖ˆV‖Awn‖12‖w′n(t)‖≤α20‖wn‖‖wn‖2ˆV‖Awn‖+14‖w′n(t)‖2 | (25) |
and
|⟨N(wn(t)),w′n(t)|≤14‖w′n(t)‖2+c2(νr)‖wn(t)‖2ˆV. | (26) |
Taking (23)-(26) into account, we obtain
‖w′n(t)‖2+2ddt⟨Awn(t),wn(t)⟩≤8‖F(t)‖2+8‖G(t,wnt)‖2+4α20‖wn‖3ˆV‖Awn(t)‖+4c2(νr)‖wn(t)‖2ˆV. |
Integrating the above inequality, yields
∫tτ+ϵ‖w′n(θ)‖dθ≤2c−11‖wn(τ+ϵ)‖2ˆV+8∫tτ+ϵ‖F(θ)‖2dθ+8∫tτ+ϵ‖G(θ,wnθ)‖2dθ+4α20∫tτ+ϵ‖wn(θ)‖3ˆV‖Awn(θ)‖dθ+4c2(νr)∫tτ+ϵ‖wn(θ)‖2ˆVdθ≤2c−11‖wn(τ+ϵ)‖2ˆV+8∫tτ+ϵ‖F(θ)‖2dθ+8C2G(∫tτ‖wn(θ)‖2ˆVdθ+∫0−h‖ϕin(s)‖2ds)+4c2(νr)∫tτ+ϵ‖wn(θ)‖2ˆVdθ,+2α20maxθ∈[τ+ϵ,t]‖wn(θ)‖2ˆV∫tτ+ϵ(‖wn(θ)‖2ˆV+‖Awn(θ)‖2)dθ |
which together with (20), Assumption 2.2 and the assertions (ⅰ)-(ⅲ) gives the assertion (ⅳ). The proof is complete.
With the above lemma, we are ready to conclude this section with the following
Theorem 3.2. Let assumptions 2.1-2.2 hold and
Proof. Based on Lemma 3.1, following the standard diagonal procedure, there exist a subsequence (denoted still by)
wn(⋅)⇀∗w(⋅) weakly star in L∞(τ+ϵ,t;ˆV), | (27) |
wn(⋅)⇀w(⋅) weakly in L2(τ+ϵ,t;D(A)), | (28) |
w′n(⋅)⇀w′(⋅) weakly in L2(τ+ϵ,t;ˆH). | (29) |
Furthermore, it follows from the uniqueness of the limit function that
Remark 3.1. We here point out that the boundedness of pullback attractor
‖(G(t,ξ))′−(G(t,η))′‖≤˜LG‖ξ−η‖L2(−h,0;ˆH). |
∫tτ‖(G(θ,wθ))′−(G(θ,vθ))′‖2dθ≤˜C2G∫tτ−h‖w(θ)−v(θ)‖2dθ. |
Then we can deduce that the Galerkin approximate solutions
In this section, we concentrate on verifying the upper semicontinuity of the pullback attractor
{∂wm∂t+Awm+B(um,wm)+N(wm)=F(t,x)+G(t,wmt),in (τ,+∞)×Ωm,∇⋅um=0,in (τ,+∞)×Ωm,wm=(um,ωm)=0, on (τ,+∞)×Γ,wm(τ)=winm, wmτ(s)=ϕinm(s), s∈(−h,0). | (30) |
On each bounded domain
Lemma 4.1. Suppose Assumption 2.1 and Assumption 2.2 hold, then for any given
wm(⋅)∈C([τ,T];ˆH(Ωm))∩L2(τ,T;ˆV(Ωm)), w′m(⋅)∈L2(τ,T;ˆV∗(Ωm)), ∀T>τ. |
Moreover, the solution
According to Lemma 4.1, the map defined by
Um(t,τ):(winm,ϕinm(s))↦Um(t,τ,winm,ϕinm(s))=(wm(t),wmt(s;τ,win,ϕin(s))), ∀t≥τ, | (31) |
generates a continuous process
Lemma 4.2. Under the assumptions 2.1 and 2.2, it holds that
BˆH(Ωm)(t)={(w,ϕ)∈E2ˆH(Ωm)×L2ˆV(Ωm)|‖(w,ϕ)‖2EˆH(Ωm)×L2ˆV(Ωm)≤R1(t)} |
is pullback
‖wm(t,τ,winm,ϕinm(s))‖L2(Ωm∖Ωr)≤ϵ, ∀(winm,ϕinm(s))∈BˆH(Ωm)(τ). |
Then based on the Remark 2.1 in [16], we conclude that
Theorem 4.3. Let assumptions 2.1 and 2.2 hold. Then there exists a pullback attractor
In the following, we investigate the relationship between the solutions of system (30) and (13). Indeed, we devoted to proving the solutions
˜wm={wm,x∈Ωm,0,x∈Ω∖Ωm, | (32) |
then it holds that
‖wm‖ˆH(Ωm)=‖˜wm‖ˆH(Ωm)=‖˜wm‖ˆH(Ω):=‖wm‖. |
Next, using the same proof as that of Lemma 8.1 in [8], we have
Lemma 4.4. Let assumptions 2.1-2.2 hold and
wm(t;τ,winm,ϕinm(s))⇀w(t;τ,win,ϕin(s)) weakly in ˆH, | (33) |
wm(⋅;τ,winm,ϕinm(s))⇀w(⋅;τ,win,ϕin(s)) weakly in L2(t−h,t;ˆV). | (34) |
Based on Lemma 4.4, we set out to prove the following important lemma.
Lemma 4.5. Let assumptions 2.1-2.2 hold, then for any
(wm(t),wmt(s))→(w(t),wt(s)) strongly in E2ˆH. | (35) |
Proof. From the compactness of pullback attractor, it follows that the sequence
(winm,ϕinm(s))⇀(win,ϕin(s)) weakly in E2ˆH×L2ˆV as m→∞. | (36) |
Further, according to Lemma 4.4 and the invariance of the pullback attractor, we can conclude that for any
(wm(t),wmt(s))⇀(w(t),wt(s)) weakly in E2ˆH×L2ˆV as m→∞. | (37) |
Then, using the same way of proof as Lemma 3.6 in [16], we can obtain that the convergence relation of (37) is strong. The proof is complete. With the above lemma, we are ready to state the main result of this section.
Theorem 4.6. Let Assumption 2.1 and Assumption 2.2 hold, then for any
limm→∞distE2ˆH(AˆH(Ωm)(t),AˆH(t))=0, | (38) |
where
Proof. Suppose the assertion (38) is false, then for any
distE2ˆH((wm(t0),wmt0(s)),AˆH(t0))≥ϵ0. | (39) |
However, it follows from Lemma 4.5 that there exists a subsequence
{(wmk(t0),wmkt0(s))}⊆{(wm(t0),wmt0(s))} |
such that
limk→∞distE2ˆH((wmk(t0),wmkt0(s)),AˆH(t0))=0, |
which is in contradiction to (39). Therefore, (38) is true. The proof is complete.
[1] |
Sun H, Saeedi P, Karuranga S, et al. (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183: 109119. https://doi.org/10.1016/j.diabres.2021.109119 ![]() |
[2] |
Malik VS, Willet WC, Hu FB (2020) Nearly a decade on—trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol 16: 615-616. https://doi.org/10.1038/s41574-020-00411-y ![]() |
[3] |
Williams DM, Nawaz A, Evans M (2020) Drug therapy in obesity: a review of current and emerging treatments. Diabetes Ther 11: 1199-1216. https://doi.org/10.1007/s13300-020-00816-y ![]() |
[4] |
Sims EK, Carr AL J, Oram RA, et al. (2021) 100 years of insulin: celebrating the past, present and future of diabetes therapy. Nat Med 27: 1154-1164. https://doi.org/10.1038/s41591-021-01418-2 ![]() |
[5] |
Arterburn DE, Telem DA, Kushner RF, et al. (2020) Benefits and risks of bariatric surgery in adults: a review. JAMA 324: 879-887. https://doi.org/10.1001/jama.2020.12567 ![]() |
[6] |
Boonpattharatthiti K, Saensook T, Neelapaijit N, et al. (2024) The prevalence of adherence to insulin therapy in patients with diabetes: A systematic review and meta-analysis. Res Social Adm Pharm 20: 255-295. https://doi.org/10.1016/j.sapharm.2023.11.009 ![]() |
[7] |
Tak YJ, Lee SY (2021) Long-term efficacy and safety of anti-obesity treatment: where do we stand?. Curr Obes Rep 10: 14-30. https://doi.org/10.1007/s13679-020-00422-w ![]() |
[8] |
Charytoniuk T, Zywno H, Berk K, et al. (2022) The endocannabinoid system and physical activity—a robust duo in the novel therapeutic approach against metabolic disorders. Int J Mol Sci 23: 3083. https://doi.org/10.3390/ijms23063083 ![]() |
[9] |
Ghasemi-Gojani E, Kovalchuk I, Kovalchuk O (2022) Cannabinoids and terpenes for diabetes mellitus and its complications: From mechanisms to new therapies. Trends Endocrinol Metab 33: 828-849. https://doi.org/10.1016/j.tem.2022.08.003 ![]() |
[10] |
Cavalheiro EKFF, Costa AB, Salla DH, et al. (2022) Cannabis sativa as a treatment for obesity: From anti-inflammatory indirect support to a promising metabolic re-establishment target. Cannabis Cannabinoid Res 7: 135-151. https://doi.org/10.1089/can.2021.0016 ![]() |
[11] |
Murray CH, Gannon BM, Winsauer PJ, et al. (2024) The development of cannabinoids as therapeutic agents in the United States. Pharmacol Rev 76: 915-955. https://doi.org/10.1124/pharmrev.123.001121 ![]() |
[12] |
Abioye A, Ayodele O, Marinkovic A, et al. (2020) Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. J Cannabis Res 2: 1-6. https://doi.org/10.1186/s42238-020-0016-7 ![]() |
[13] |
Peters EN, MacNair L, Harrison A, et al. (2023) A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. Cannabis Cannabinoid Res 8: S71-S82. https://doi.org/10.1089/can.2023.0038 ![]() |
[14] | Haghdoost M, Peters EN, Roberts M, et al. (2025) Tetrahydrocannabivarin is Not Tetrahydrocannabinol. Cannabis Cannabinoid Res 10: 1-5. https://doi.org/10.1089/can.2024.0051 |
[15] |
Kowalczuk A, Marycz K, Kornicka J, et al. (2023) Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis. Int J Mol Sci 24: 7120. https://doi.org/10.3390/ijms24087120 ![]() |
[16] |
Svízenská I, Dubový P, Sulcová A (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol Biochem Behav 90: 501-511. https://doi.org/10.1016/j.pbb.2008.05.010 ![]() |
[17] |
Kurtov M, Rubinić I, Likić R (2024) The endocannabinoid system in appetite regulation and treatment of obesity. Pharmacol Res Perspect 12: e70009. https://doi.org/10.1002/prp2.70009 ![]() |
[18] | Rohbeck E, Eckel J, Romacho T (2021) Cannabinoid Receptors in Metabolic Regulation and Diabetes. Physiology (Bethesda) 36: 102-113. https://doi.org/10.1152/physiol.00029.2020 |
[19] |
Englund A, Atakan Z, Kralj A, et al. (2016) The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol 30: 140-151. https://doi.org/10.1177/0269881115615104 ![]() |
[20] |
Mackie K, Ross RA (2008) CB2 cannabinoid receptors: new vistas. Br J Pharmacol 153: 177-178. https://doi.org/10.1038/sj.bjp.0707617 ![]() |
[21] |
Bátkai S, Mukhopadhyay P, Horváth B, et al. (2012) Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol 165: 2450-2461. https://doi.org/10.1111/j.1476-5381.2011.01410.x ![]() |
[22] |
Wargent ET, Zaibi MS, Silvestri C, et al. (2013) The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes 3: e68. https://doi.org/10.1038/nutd.2013.9 ![]() |
[23] |
Wargent ET, Kepczynska M, Zaibi MS, et al. (2020) High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain. PeerJ 8: e9811. https://doi.org/10.7717/peerj.9811 ![]() |
[24] |
Jadoon KA, Ratcliffe SH, Barrett DA, et al. (2016) Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care 39: 1777-1786. https://doi.org/10.2337/dc16-0650 ![]() |
[25] |
Riedel G, Fadda P, McKillop-Smith S, et al. (2009) Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156: 1154-1166. https://doi.org/10.1111/j.1476-5381.2008.00107.x ![]() |
[26] |
Silvestri C, Paris D, Martella A, et al. (2015) Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. J Hepatol 62: 1382-1390. https://doi.org/10.1016/j.jhep.2015.01.001 ![]() |
[27] | Tudge L, Williams C, Cowen PJ, et al. (2014) Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol 18: pyu094. https://doi.org/10.1093/ijnp/pyu094 |
[28] |
Stella N (2023) THC and CBD: Similarities and differences between siblings. Neuron 111: 302-327. https://doi.org/10.1016/j.neuron.2022.12.022 ![]() |
[29] |
Farrimond JA, Mercier MS, Whalley BJ, et al. (2011) Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Phytother Res 25: 170-188. https://doi.org/10.1002/ptr.3375 ![]() |
[30] |
Naef M, Curatolo M, Petersen-Felix S, et al. (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105: 79-88. https://doi.org/10.1016/S0304-3959(03)00163-5 ![]() |
[31] |
Peng J, Fan M, An C, et al. (2022) A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol 130: 439-456. https://doi.org/10.1111/bcpt.13710 ![]() |
[32] |
Luo X, Reiter MA, d'Espaux L, et al. (2019) Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. Nature 567: 123-126. https://doi.org/10.1038/s41586-019-0978-9 ![]() |
[33] |
Bolaños-Martínez OC, Malla A, Rosales-Mendoza S, et al. (2023) Harnessing the advances of genetic engineering in microalgae for the production of cannabinoids. Crit Rev Biotechnol 43: 823-834. https://doi.org/10.1080/07388551.2022.2071672 ![]() |
[34] |
Deiana S, Watanabe A, Yamasaki Y, et al. (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 219: 859-873. https://doi.org/10.1007/s00213-011-2415-0 ![]() |
[35] |
Mead A (2019) Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States. Front Plant Sci 10: 697. https://doi.org/10.3389/fpls.2019.00697 ![]() |
[36] |
Senatore F (2023) Good Clinical Practice in Clinical Trials, Substantial Evidence of Efficacy, and Interpretation of the Evidence. The Quintessence of Basic and Clinical Research and Scientific Publishing . Singapore: Springer Nature Singapore 373-385. https://doi.org/10.1007/978-981-99-1284-1_23 ![]() |
[37] |
Loganathan P, Gajendran M, Goyal H (2024) A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome. Pharmaceuticals (Basel) 17: 1549. https://doi.org/10.3390/ph17111549 ![]() |
[38] |
Groening JM, Denton E, Parvaiz R, et al. (2024) A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review of systematic reviews and meta-analyses. Psychiatry Res 331: 115626. https://doi.org/10.1016/j.psychres.2023.115626 ![]() |
[39] |
Cheng Z, Zheng L, Almeida FA (2018) Epigenetic reprogramming in metabolic disorders: nutritional factors and beyond. J Nutr Biochem 54: 1-10. https://doi.org/10.1016/j.jnutbio.2017.10.004 ![]() |
1. | Shuyang Chen, Dependency ratio and emission trading scheme: a case study in China, 2023, 176, 0165-0009, 10.1007/s10584-023-03651-9 | |
2. | Shuyang Chen, Equality and efficiency tradeoffs in revenue recycling of emission trading scheme: a case study on the recent chinese national ETS market, 2024, 1573-2975, 10.1007/s10668-024-05380-0 | |
3. | Shuyang Chen, Impacts of emission trading scheme on technological progress: A case study in China, 2024, 10, 24058440, e23126, 10.1016/j.heliyon.2023.e23126 | |
4. | Xiangsong Ye, Longju Zhou, Zhiyong Wang, Spatial convergence characteristics of low carbon economy and economic growth quality: based on Guangdong urban data, 2024, 9, 2473-6988, 11660, 10.3934/math.2024572 |